1. Home
  2. MTEK vs PHIO Comparison

MTEK vs PHIO Comparison

Compare MTEK & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.62

Market Cap

12.6M

Sector

N/A

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.25

Market Cap

13.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
PHIO
Founded
2008
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
13.5M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
MTEK
PHIO
Price
$1.62
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.67
AVG Volume (30 Days)
1.3M
667.1K
Earning Date
01-01-0001
06-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.81
52 Week High
$4.27
$4.19

Technical Indicators

Market Signals
Indicator
MTEK
PHIO
Relative Strength Index (RSI) 43.67 55.32
Support Level $1.48 $1.01
Resistance Level $1.57 $1.43
Average True Range (ATR) 0.24 0.08
MACD -0.04 0.01
Stochastic Oscillator 8.93 85.58

Price Performance

Historical Comparison
MTEK
PHIO

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: